Number of Employee Profiles 2. Bond Biosciences has 2 current employee profiles, including Co-founder and Chief Scientific Officer Cory Berkland. Cory Berkland Co-founder and Chief Scientific Officer.Cory Berkland. Chemical & Petroleum Engineering, 1530 West 15th Street, University of Kansas, Lawrence, Kansas 66045-7609. Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence, Kansas 66045-7609. Search for more papers by this authorCory J. Berkland's 12 research works with 58 citations and 516 reads, including: Sorbents for treatment of hereditary hemochromatosisIntercellular cell-adhesion molecule-1 (ICAM-1) is up-regulated on the vascular endothelium in response to pro-inflammatory cytokines produced in the synovial cavity of patients with Rheumatoid Arthritis.Chandrashekar Raman 1 , Cory Berkland, Kyekyoon Kim, Daniel W Pack. Affiliation 1 Department of Chemical and Biomolecular Engineering, University of Illinois, Urbana, IL 61801, United States. PMID: 15773062 DOI: 10.1016/j.jconrel.2004.11.012 Abstract Modeling release of small molecules from degradable microspheres is important to the design of ...Berkland C, King M, Cox A, Kim K, Pack DW. Precise control of PLG microsphere size provides enhanced control of drug release rate . Journal of Controlled Release . 2002 Jul 18;82(1):137-147. doi: 10.1016/S0168-3659(02)00136-Deanna Diaz, Emporia, is a sophomore at KU studying chemical engineering. Diaz is in the IMSD program and mentored by Cory Berkland, professor of pharmaceutical chemistry. Marissa Duckett, Oklahoma City, is a sophomore at KU studying microbiology.Cory Berkland, CEO [email protected]. Release Summary. Phase Ia/b will assess the safety of BBI-001 and test the ability of BBI-001 to prevent iron uptake from food. Contacts.3. The student ban is cruel. Expelling students in the middle of a pandemic serves no useful purpose. It does not increase their safety or the safety of U.S. nationals.Cory Berkland View For the in vitro release experiment, 50 µl of UM-3003 adsorbed alhydrogel formulation was mixed with 500 µl of adjuvant-free human plasma in a closed glass vial at 37 °C and ...Cory Berkland 2 Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS. 6 Bioengineering Graduate Program, University of Kansas, Lawrence, KS. 7 Department of Chemical and Petroleum Engineering, University of Kansas, Lawrence, KS. Search for other works by this author on: This Site.Recently, lymphocyte function-associated antigen-1 (LFA-1), a primary cell adhesion molecule, has also been investigated for targeting nanoparticles to human leukemic cell line ( 30, 32 ). Lima et al. reported that certain leukemic cells expressed 5-fold more LFA-1 than normal leukocytes ( 32 ). Since LFA-1 is expressed only on leukocytes, it ... Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer Yumei Xiea, Kristin L. Aillona, Shuang Caia, Jason M. Christianb, Neal M. Daviesc, Cory J. Berklanda,b, and M. Laird Forresta,* aDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, 66047 USA bDepartment of Chemical and Petroleum Engineering, University of ...Brittany L. Hartwell, 1 Chad J. Pickens, 2 Martin Leon, 3 Laura Northrup, 2 Matthew Christopher, 2 J. Daniel Griffin, 1 Francisco Martinez-Becerra, 4 and Cory Berkland 1, 2, 5, * Brittany L. Hartwell 1 Bioengineering Graduate Program, University of Kansas 1520 West 15 th Street, Lawrence, KS 66045, USAA leading strategy in tissue engineering is the design of biomimetic scaffolds that stimulate the body's repair mechanisms through the recruitment of endogenous stem cells to sites of injury. Approaches that employ the use of chemoattractant gradients to guide tissue regeneration without external ce …Bradley J. Newell. Interim Assistant Dean - Wichita. Director - PGY-1 Community-Based Pharmacy Residency (DIllons) Clinical Assistant Professor. School of Pharmacy - Administration. Department of Pharmacy Practice. Dept. of Family & Community Med., KU Med., Wichita. View full profile.The long-term objective of this application is to deliver a unique biomaterial that can easily be molded into place by a surgeon, and will resorb as it induces rapid tissue regeneration. Toward this o...Cory Berkland, Chief Executive Officer of Bond, commented that "we are highly encouraged by these results, which demonstrate the mechanism and clinical activity of BBI-001 after just a single dose.BERKLAND CORY, MOHAMMADI ZAHRA. Author information. Affiliations. All authors. 1. UNIV KANSAS Patent: Publ.of the Int.Appl. with Int.search report - World Intellectual Property Organization Application: WO2011US26872 on 02 Mar 2011 Publication: 02 Mar 2011 PAT: WO2011109521 ...Cory Berkland, CEO [email protected]. Release Summary. Phase Ia/b will assess the safety of BBI-001 and test the ability of BBI-001 to prevent iron uptake from food. Contacts.Nabil Alhakamy • Cory Berkland • Jin Chen • Dana Brantley-Sieders • Nikki Cheng Received: 4 December 2014/Accepted: 24 February 2015/Published online: 6 March 2015 Springer Science+Business Media New York 2015 Abstract Luminal A and B breast cancers are the most prevalent forms of breast cancer diagnosed in women. Cory Berkland. Solon E. Summerfield Distinguished Professor ; PHARMACEUTICAL CHEMISTRY; Contact Info. 785-864-1455. Multidisciplinary Research Building, Room 320D 2030 Becker Drive Lawrence, KS 66047 Learned Hall, Room 4160C 1530 West 15th Street Lawrence, KS 66045 Personal Links.Sep 1, 2022 · Abstract: Particles for delivery of active ingredients formed from an active ingredient and a hydrophobic matrix, as well as methods for making such particles. Type: Grant. Filed: August 16, 2019. Date of Patent: February 14, 2023. Assignee: ADARE PHARMACEUTICALS USA, INC. Inventors: Cory Berkland, Milind Singh. Cory Berkland and Nathan Dormer look at what controlled-release powder delivery systems can offer, noting that a rising number of pharmaceutical companies and manufacturing organisations are incorporating controlled-release powder manufacturing to their portfolios.AU - Berkland, Cory. AU - Kim, Kyekyoon. AU - Pack, Daniel W. N1 - Funding Information: This work was partly supported by NIH grant EB002878. We would like to thank Larry Markoski and Prof. Jeff Moore for helping us with their time and equipment to make SEC measurements. The piroxicam gift from Dongwha Pharmaceuticals is also gratefully ...Practical Considerations, Challenges, and Limitations of Bioconjugation via Azide-Alkyne Cycloaddition Chad J. Pickens1, Stephanie N. Johnson1, Melissa M. Pressnall1, Martin A. Leon2, and Cory J. Berkland1,2 1Department of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Avenue, Lawrence, Kansas 66047, USADr. Cory J. Berkland, Committee Chair February 3rd, 2015_____ Date approved . iii ABSTRACT Self-assembling and shear-responsive biomaterials possess favorable rheological and viscoelastic properties to be injectable and facilitate minimally invasive surgery. The current thesis workGlobalization of Pharmaceutics Education Network (GPEN) Founded in 1996 by the KU Department of Pharmaceutical Chemistry in cooperation with several educational institutions in Europe and Asia, GPEN, Inc. was created for the sole purpose of fostering and facilitating international scientific exchange in the pharmaceutical sciences.Charles Allen Thomas Professor of Chemistry, Chair and Professor of Chemistry. John . HeemstraIt's a spin-off from the laboratory of Distinguished Professor of Pharmaceutical Chemistry and Chemical & Petroleum Engineering Cory Berkland. KU's 280,000-square-foot Integrated Science Building opened in 2018 and is home to world-class laboratory and classroom space for cutting-edge research in bioengineering, chemistry, medicinal ...Biography —. Distinguished Professor of Chemical and Petroleum Engineering and Pharmaceutical Chemistry.Author links open overlay panel Emily J. Pollauf a, Cory Berkland a 1, Kyekyoon (Kevin) Kim b c, Daniel W. Pack a c. Show more. Add to Mendeley. Share. Cite. ... (Berkland et al., 2004a). Further, polymer chemistry and the mechanisms of degradation and erosion of the shell- and core-forming materials add a tunable parameter to such a delivery ...Bond Biosciences has a strong board and managment team with significant industry experience including Cory Berkland, Mike Riley, Tim Opler and Mike Beckloff.J Daniel Griffin Sebastian G Huayamares Towne R Walston Jimmy Y Song Michael Shao Alexander R Sedlacek Deanna L Diaz Aparna R Chakravarti Cory J Berkland ACS Appl Bio Mater 2021 01 23;4(1):387-391. Epub 2020 Dec 23.The company’s lead candidate, BBI-001, is an iron chelator for the treatment of hereditary hemochromatosis. Bond joins the St. Louis ecosystem after licensing technology originally developed at the University of Kansas. Bond was founded by St. Louisan and serial entrepreneur Cory Berkland, PhD.Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer Yumei Xiea, Kristin L. Aillona, Shuang Caia, Jason M. Christianb, Neal M. Daviesc, Cory J. Berklanda,b, and M. Laird Forresta,* aDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, 66047 USA bDepartment of Chemical and Petroleum Engineering, University of ...LAWRENCE — Cory Berkland might not be the first person you'd guess would help to create what has become a multimillion-dollar company. The distinguished professor, appointed in the departments of Pharmaceutical Chemistry and Chemical & Petroleum Engineering at the University of Kansas, grew up on a pig farm in Iowa, studied chemical engineering at the undergraduate and graduate levels and ...Jim Berkland. James O. Berkland (July 31, 1930 – July 22, 2016) was an American geologist [1] who controversially claimed to be able to predict earthquakes, including the 1989 Loma Prieta earthquake and 1994 Northridge Earthquake [2] and who popularized the idea that some people are earthquake sensitive. He was profiled in a popular 2006 book ...Jun 30, 2023 · Cory Berkland joins the faculty Nov. 1 from The University of Kansas, where he is the Solon E. Summerfield Distinguished Professor of Chemical and Petroleum Engineering and Pharmaceutical Chemistry. He has been on the faculty since 2003. If delivered as a suspension, such small particles are also prone to particle growth due to Ostwald ripening and can suffer from uncontrolled agglomeration (Berkland, 2010). A major obstacle to inhaled therapeutics is the inability to efficiently deliver large quantities of a drug to the deep lung (Gillian, 2010).Todd Berkland Work Experience and Education. According to ZoomInfo records, Todd Berkland`s professional experience began in 2000. Since then Todd has changed 4 companies and 3 roles. Currently, Todd Berkland works as a Vice President, Business Development & Acquisitions at Wrench Group.Cory Berkland has 3 current jobs including Co-founder and Chief Executive Officer at Bond Biosciences, Co-founder and Chief Scientific Officer at Bond Biosciences, and Solon E. Summerfield Distinguished Professor at University of Kansas. Additionally, Cory Berkland has had 1 past job as the Chief Science/Scientist at Orbis Biosciences.Berkland Cory [email protected]. Biomaterial(s) Drug delivery system(s) Polymeric biomaterial(s) Polymeric drug delivery system(s) Last Name First Name. Email Address Keywords. Bhambhani Akhilesh [email protected]. Biopharmaceutical characterization. Freeze-drying Gene therapy.Europe PMC is an archive of life sciences journal literature.Brian T. Andrews, Scott Barbay, Sheila Tsau, Cory Berkland, Jakob M. Townsend, Michael S. Detamore, Chad A. Tuchek, Randolph J. Nudo Effects of distance and transport method on intervention and ...What We Do. Our lab works at the interface of medicine and engineering with an emphasis on precisely controlling the physical and chemical properties of particles and biomaterials. The lab environment fosters multidisciplinary interaction between graduate and undergraduate researchers from the departments of Chemical and Petroleum …The most common forms of proteosomes used for vaccine applications are nanoparticles composed of the outer membrane proteins (OMPs) of Neisseria meningitidis. OMPs have been used successfully in a marketed meningococcal vaccine since 1981 and are considered non-toxic and well-tolerated [160], [161].Chittasupho C, Shannon L, Siahaan TJ, Vines CM, Berkland C. Nanoparticles targeting dendritic cell surface molecules effectively block T cell conjugation and shift response. ACS Nano. 2011; 5 (3):1693–702. doi: 10.1021/nn102159g. [Europe PMC free article] [Google Scholar]Photo: Bryce Stottlemire, a doctoral student in bioengineering, displays one of the face shields designed and fabricated in the labs of Mei He, assistant professor of chemical & petroleum engineering, and Cory Berkland, Solon E. Summerfield Distinguished Professor of Pharmaceutical Chemistry.Oct 9, 2014 · Chittasupho C, Sestak J, Shannon L, Siahaan TJ, Vines CM, Berkland C. Hyaluronic acid graft polymers displaying peptide antigen modulate dendritic cell response in vitro. Mol Pharm. 2013;11(1):367–73. doi: 10.1021/mp4003909. AU - Berkland, Cory. N1 - Funding Information: We gratefully acknowledge support from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (R56 AI091996), the National Institute of General Medical Sciences (T32 GM008359), the Kansas IDeA Network of Biomedical Research Excellence, the PhRMA Foundation ...The magnolia plant has been used in traditional medicine since ancient times. This study was designed to investigate the effects of active compounds from Thai Champi Sirindhorn (Magnolia sirindhorniae) on leukemic biomarker Wilms' tumor 1 (WT1) protein expressions in K562 and Molt-4 cells.Costunolide (1) and parthenolide (2) were the major components used in this study, they were purified ...The most common forms of proteosomes used for vaccine applications are nanoparticles composed of the outer membrane proteins (OMPs) of Neisseria meningitidis. OMPs have been used successfully in a marketed meningococcal vaccine since 1981 and are considered non-toxic and well-tolerated [160], [161].Qun Wanga, Syed Jamalb, Michael S. Detamorea, and Cory Berklanda,c,* a Department of Chemical and Petroleum Engineering, University of Kansas, Lawrence, KS 66047 b Department of Molecular Biosciences, University of Kansas, Lawrence, KS 66047 c Department of Pharmaceutical Science, University of Kansas, Lawrence, KS 66047 AbstractBrittany L. Hartwell, Aaron Smalter Hall, David Swafford, Bradley P. Sullivan, Aaron Garza, Joshua O. Sestak, Laura Northrup, and Cory Berkland. Molecular Dynamics of Multivalent Soluble Antigen Arrays Support a Two-Signal Co-delivery Mechanism in the Treatment of Experimental Autoimmune Encephalomyelitis.Prof. Berkland is a co-founder of Orbis Biosciences, Savara Pharmaceuticals, Bond Biosciences and Orion BioScience. He is also a co-developer of several technologies with industrial partners. He...Berkland C, Kim K, Pack DW. PLG microsphere size controls drug release rate through several competing factors . Pharmaceutical Research . 2003 Jul 1;20(7):1055-1062. doi: 10.1023/A:10244664078491. Introduction. Injectable scaffolds have received attention due to their potential for avoiding the invasive surgery typically required for tissue implantation. 1 From a clinical perspective, the use of injectable materials is an attractive alternative to surgery as it reduces the risk of infection, scar formation, patient discomfort and the cost of treatment. 2 Injectable scaffolds may be ...How it works: Cory Berkland, Ph.D., professor at the University of Kansas, is a serial entrepreneur, co-founding Orbis Biosciences, Savara Pharmaceuticals and Orion Biosciences, as well as co-developing several technologies with industry partners. In late 2012, IAMI invested in novel polymer technology discovered by Dr. Berkland with the intent ...Cory Berkland is a professor in the Engineering department at University of Kansas - see what their students are saying about them or leave a rating yourself. ... Professor Berkland's Top Tags. Test heavy Graded by few things. Check out Similar Professors in the . Engineering Department 5.00 Caroline Bennett; 5.00 James Stiles;BERKLAND CORY, MOHAMMADI ZAHRA. Author information. Affiliations. All authors. 1. UNIV KANSAS Patent: Publ.of the Int.Appl. with Int.search report - World Intellectual Property Organization Application: WO2011US26872 on 02 Mar 2011 Publication: 02 Mar 2011 PAT: WO2011109521 ...Jonathan Miller and Cory Berkland discovered and provisionally patented the soft 3D force sensing technology while working on federally funded smart materials research at the …Chad J Pickens 1 , Stephanie N Johnson 1 , Melissa M Pressnall 1 , Martin A Leon 2 , Cory J Berkland 1 2 3 Affiliations 1 Department of Pharmaceutical Chemistry , University of Kansas , 2095 Constant Avenue , Lawrence , Kansas 66047 , United States.C. Berkland et al. Precise control of PLG microsphere size provides enhanced control of drug release rate. J. Control. Release (2002) ... Cory Berkland. Protein Encapsulation in and Release from Monodisperse Double-Wall Polymer Microspheres. Journal of Pharmaceutical Sciences, Volume 102, Issue 5, 2013, pp. 1601-1609 ...Cory Berkland1,2,* 1 Department of Pharmaceutical Chemistry, University of Kansas, 2030 Becker Dr, Lawrence, KS ... *Corresponding Author; [email protected]. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to ourCory Berkland, Ph.D. Abstract Basic principles have emerged for oral and intravenous drug design, but fewer efforts have ... Berkland is a co-founder of Orbis Biosciences (purchased by Adare Pharmaceuticals), Savara Pharmaceuticals (NASDAQ: SVRA), Bond Biosciences, and Orion BioScience. Title: Microsoft Word - Cory Berkland Seminar Announcement ...Name: CORY BERKLAND Phone: (785) 864-1455 Email: [email protected]. Business Contact. Name: CORY BERKLAND Phone: (785) 764-0125 Email: [email protected]. Research Institution. N/A . Abstract. PROJECT SUMMARY/ABSTRACT Hereditary Hemochromatosis (HH) is one of the most common genetic disorders in the United States affectingIn recent history, through the merger of engineering and biological sciences, biotechnology has pressed toward improving methods for regenerating tissues, developing biosensors, and effectively delivering therapeutic agents.... Cory J. Berkland,1,4 Cato T. Laurencin,2,3,5 and Michael S. Detamore6. 1Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66045 ...Cory Berkland Mario Rivera Kate ESHELMAN Jian QIAN Nashwa EL-GENDY Original Assignee The University Of Kansas Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2014-10-10 Filing date 2015-10-08 Publication ...J Daniel Griffin Sebastian G Huayamares Towne R Walston Jimmy Y Song Michael Shao Alexander R Sedlacek Deanna L Diaz Aparna R Chakravarti Cory J Berkland ACS Appl Bio Mater 2021 01 23;4(1):387-391. Epub 2020 Dec 23.Home. Cory Berkland. Distinguished Professor, Pharmaceutical Chemistry. Professor, Chemical & Petroleum Engineering. Contact Info. [email protected]. 785-864-1455. …El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res. 2009; 26:1752-1763. [PMC free article] [Google Scholar] El-Gendy N, et al. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci. 2009; 98:2731-2746.Nashwa El-Gendy1,3, Warangkana Pornputtapitak1, and Cory Berkland1,2,* 1Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66047. ... Fax: (001) 785- 864- 1454. [email protected]. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to ourMin Huang 1 , Samadhi N Vitharana, Laura J Peek, Tina Coop, Cory Berkland. Affiliation 1 Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas 66047, USA. PMID: 17428030 DOI: 10.1021/bm061211k Abstract Angiogenesis has long been a desired therapeutic approach to improve clinical outcomes of conditions typified by ...Prof. Berkland is a co-founder of Orbis Biosciences, Savara Pharmaceuticals, Bond Biosciences and Orion BioScience. He is also a co-developer of several technologies with industrial partners. He... Dr. Cory J. Berkland, Committee Chair February 3rd, 2015_____ Date approved . iii ABSTRACT Self-assembling and shear-responsive biomaterials possess favorable rheological and viscoelastic properties to be injectable and facilitate minimally invasive surgery. The current thesis workCory Berkland 1 , Martin King, Amanda Cox, Kyekyoon Kim, Daniel W Pack. Affiliation 1 Department of Chemical Engineering, University of Illinois, MC-712, Box C-3, 600 South Mathews Avenue, Urbana, IL 61801, USA. PMID: 12106984 PMCID: PMC4140625 DOI: 10.1016/s0168-3659(02 ...Nashwa El-Gendy1,3, Warangkana Pornputtapitak1, and Cory Berkland1,2,* 1Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66047. ... Fax: (001) 785- 864- 1454. [email protected]. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to ourThe toll-like receptor 7 and 8 (TLR7/8) agonist Resiquimod (R848) has been recognized as a promising immunostimulator for the treatment of cutaneous cancers in multiple clinical trials. However, systemic administration of R848 often results in strong immune-related toxicities while having limited th …Europe PMC is an archive of life sciences journal literature.Aug 2, 2016 · Fang WB, Yao M, Jokar I, Alhakamy N, Berkland C, Chen J, Brantley-Sieders D, Cheng N. The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells. Breast Cancer Res Treat. Sep 6, 2014 · The induction of immune response by presentation of antigen on or with immune stimulating “signal” is a primary design metric of vaccines. We rationalized that a similar strategy could also be used to design antigen-SITs to induce tolerance to autoantigen. Both approaches focus on the recognition, attack, and removal of a “foreign ... Singh M, Morris CP, Ellis RJ, Detamore MS, Berkland C. Microsphere-Based Seamless Scaffolds Containing Macroscopic Gradients of Encapsulated Factors for Tissue Engineering. Tissue Eng Part C Methods. 2008; 14:299–309. [Europe PMC free article] [Google Scholar]Adding trainee for Cory Berkland Type a name and select match from the drop-down list. If no match exists, you will be prompted to add a new person to the tree. Name: School: Department: Relationship: Comments: Cancel Save. Adding mentor for Cory Berkland Type a name and select match from the drop-down list. ...Abstract. Lung surfactant is crucial for optimal pulmonary function throughout life. An absence or deficiency of surfactant can affect the surfactant pool leading to respiratory distress. Even if the coupling between surfactant dysfunction and the underlying disease is not always well understood, using exogenous surfactants as replacement is ...Dr. Vincent H. Key is a Orthopedist in Kansas City, KS. Find Dr. Key's phone number, address, insurance information, hospital affiliations and more.Cory Berkland Laird Forrest Michael Hageman Jeff Krise Sue Lunte Russ Middaugh Christian Schöneich Teruna Siahaan John Stobaugh Thomas Tolbert David Volkin Michael Wang Undergraduate Research Program ...Corresponding Author. Cory Berkland. [email protected]; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS, 66047 USA. E-mail: [email protected]; [email protected] Search for more papers by this authorQingting Hu, 1 Megan Myers, 1 Wei Fang, 1 Min Yao, 1 Gage Brummer, 1 Justin Hawj, 1 Curtis Smart, 1 Cory Berkland, 2 and Nikki Cheng 1, 3, * Qingting Hu 1 Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USAAbout KU Pharmaceutical Chemistry. The collaborative research env, Oct 11, 2021 · Cory J. Berkland [email protected] Department of Chemical and , Cory Berkland, Ph.D. -Solon E. Summerfield Distinguished Professor -Chemical , Founded Date Aug 31, 2016. Founders Cory Berkland. Operating Status Active. Last Funding Type Series B, Cory J. Berkland [email protected] Department of Chemical and Petroleu, Veisi, Masoumeh , Johnson, Stephen , Peltier, Karen , Berkl, Joe Scherrer. Executive Director, Henry Edwin Sever Institute Director, Cybersecurity Strategic Initiative Progra, Photo: Bryce Stottlemire, a doctoral student in bioengineerin, Cory Berkland is a professor of pharmaceutical chemistry and chemical, What We Do. Our lab works at the interface of medicine and eng, A cyclic peptide, cIBR, possesses high affinity for L, Cory Berkland. The Berkland Lab investigates pharmaceuticals and, Cory Berkland. Chemical & Petroleum Engineering, 1530 West 1, Chad J Pickens 1 , Stephanie N Johnson 1 , Melissa M Pre, El-Gendy Nashwa, Huang Shan, Selvam Parthiban, Soni Pravin, Berkland , The potential of this polymer for siRNA delivery was assessed. Thi, Chittasupho C, Sestak J, Shannon L, Siahaan TJ, Vine, Cory Berkland will join Washington University in St. Louis as a .